In another advanced non-squamous NSCLC cohort of patients treated with immunotherapy (Hellmann Cohort [24], Supplementary Table 3), all patients with EPHA5 mutation (nonsynonymous_snv) presented durable clinical benefit (Supplementary Figure 1A) and had high TMB (TMB > 314 mutations, i.e., the top 25% of patients, Supplementary Figure 1B). This evidence concerns the gene EPHA5 and non-small cell lung carcinoma.